Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Citronensäure-Monohydrat→

Citronensäure-Monohydrat Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
5949-29-1
Molecular formula
C6H10O8
Molecular weight
210.14 g/mol
Drug class
Citric acid monohydratepharmaceutical acidifying and buffering excipient
Mechanism of action
Dissociates in aqueous systems to provide citrate and hydrogen ions, adjusting pH and buffering capacity. It is mainly used as a formulation excipient or chemical reagent rather than a therapeutic API.
Indications / reported uses
  • Used as a pH adjuster, acidifying agent, buffer component or excipient in pharmaceutical and food formulations; no general therapeutic API indication should be assigned

Sources: USP–NF — Citric acid monohydrate monograph · PubChem — Citric acid monohydrate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Citronensäure-Monohydrat Environmental Risk Assessment (ERA) (the Citronensäure-Monohydrat ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.